CN103415285A - 包含阿片样激动剂和被隔离的拮抗剂的药物组合物 - Google Patents

包含阿片样激动剂和被隔离的拮抗剂的药物组合物 Download PDF

Info

Publication number
CN103415285A
CN103415285A CN2012800076033A CN201280007603A CN103415285A CN 103415285 A CN103415285 A CN 103415285A CN 2012800076033 A CN2012800076033 A CN 2012800076033A CN 201280007603 A CN201280007603 A CN 201280007603A CN 103415285 A CN103415285 A CN 103415285A
Authority
CN
China
Prior art keywords
antagonist
agonist
naltrexone
weight
layer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2012800076033A
Other languages
English (en)
Chinese (zh)
Inventor
E·S·威尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpharma Pharmaceuticals LLC
Original Assignee
Alpharma Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals LLC filed Critical Alpharma Pharmaceuticals LLC
Publication of CN103415285A publication Critical patent/CN103415285A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN2012800076033A 2011-02-02 2012-01-25 包含阿片样激动剂和被隔离的拮抗剂的药物组合物 Pending CN103415285A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161438882P 2011-02-02 2011-02-02
US61/438,882 2011-02-02
PCT/IB2012/050348 WO2012104752A1 (en) 2011-02-02 2012-01-25 Pharmaceutical composition comprising opioid agonist and sequestered antagonist

Publications (1)

Publication Number Publication Date
CN103415285A true CN103415285A (zh) 2013-11-27

Family

ID=45607315

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2012800076033A Pending CN103415285A (zh) 2011-02-02 2012-01-25 包含阿片样激动剂和被隔离的拮抗剂的药物组合物

Country Status (14)

Country Link
US (1) US20140141090A1 (enExample)
EP (1) EP2670400A1 (enExample)
JP (3) JP2014504630A (enExample)
KR (4) KR20160031038A (enExample)
CN (1) CN103415285A (enExample)
AU (3) AU2012213056A1 (enExample)
BR (1) BR112013019431A2 (enExample)
CA (1) CA2824835A1 (enExample)
IL (1) IL227770A0 (enExample)
MX (1) MX2013008225A (enExample)
RU (1) RU2013136350A (enExample)
SG (1) SG191872A1 (enExample)
WO (1) WO2012104752A1 (enExample)
ZA (1) ZA201305108B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111629758A (zh) * 2017-10-09 2020-09-04 罗兹制药公司 药物树脂化物组合物及其制备和使用方法

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
MX377251B (es) 2010-03-24 2025-03-07 Jazz Pharmaceuticals Inc Star Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12478604B1 (en) 2016-07-22 2025-11-25 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
AU2019383389A1 (en) 2018-11-19 2021-05-06 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
KR20230071228A (ko) 2021-11-16 2023-05-23 김명진 가상공간에 사용자가 마시는 주류를 적용하기 위한 방법 및 장치
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1183048A (zh) * 1996-01-08 1998-05-27 阿斯特拉公司 含质子泵抑制剂和nsaid的口服药物剂型
CN2423892Y (zh) * 2000-04-30 2001-03-21 尹为民 分隔式药物胶囊
CN101461809A (zh) * 2007-12-18 2009-06-24 重庆药友制药有限责任公司 一种泮托拉唑钠肠溶片及其制备方法
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4293539A (en) 1979-09-12 1981-10-06 Eli Lilly And Company Controlled release formulations and method of treatment
GB9104854D0 (en) 1991-03-07 1991-04-17 Reckitt & Colmann Prod Ltd Sustained release compositions
US5656295A (en) 1991-11-27 1997-08-12 Euro-Celtique, S.A. Controlled release oxycodone compositions
US5266331A (en) 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
DE60138706D1 (de) 2000-02-08 2009-06-25 Euro Celtique Sa Missbrauchssichere orale opioid-agonist zubereitungen
WO2002092059A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant opioid dosage form
DK1414451T3 (da) * 2001-08-06 2009-08-10 Euro Celtique Sa Opioidagonistformuleringer med frigivelig og sekvenstreret antagonist
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
DE10353196A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform mit einer die Abgabe einer modulatorischen Substanz beeinflussenden Matrix
DE10353186A1 (de) 2003-11-13 2005-06-16 Röhm GmbH & Co. KG Mehrschichtige Arzneiform, enthaltend eine in Bezug auf die Wirkstoffabgabe modulatorisch wirkende Substanz
US7201920B2 (en) 2003-11-26 2007-04-10 Acura Pharmaceuticals, Inc. Methods and compositions for deterring abuse of opioid containing dosage forms
EP1755556A4 (en) 2004-05-04 2009-09-30 Innophos Inc DIRECTLY COMPRESSIBLE TRICALCIUM PHOSPHATE
MX2008016372A (es) 2006-06-19 2009-05-28 Alpharma Inc Composiciones farmaceuticas.
AU2007322269A1 (en) * 2006-10-11 2008-05-29 Alpharma Pharmaceuticals, Llc Pharmaceutical compositions
EP2224805A4 (en) * 2007-12-17 2013-10-16 Alpharma Pharmaceuticals Llc PHARMACEUTICAL COMPOSITION
JP2013540807A (ja) * 2010-10-26 2013-11-07 アルファーマ ファーマシューティカルズ エルエルシー オピオイド過量投与によって誘発される呼吸抑制を減弱する製剤および方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1183048A (zh) * 1996-01-08 1998-05-27 阿斯特拉公司 含质子泵抑制剂和nsaid的口服药物剂型
CN2423892Y (zh) * 2000-04-30 2001-03-21 尹为民 分隔式药物胶囊
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition
CN101461809A (zh) * 2007-12-18 2009-06-24 重庆药友制药有限责任公司 一种泮托拉唑钠肠溶片及其制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111629758A (zh) * 2017-10-09 2020-09-04 罗兹制药公司 药物树脂化物组合物及其制备和使用方法

Also Published As

Publication number Publication date
US20140141090A1 (en) 2014-05-22
ZA201305108B (en) 2014-09-25
KR20190014577A (ko) 2019-02-12
WO2012104752A1 (en) 2012-08-09
BR112013019431A2 (pt) 2020-10-27
KR20180027641A (ko) 2018-03-14
JP2017081942A (ja) 2017-05-18
AU2016200708A1 (en) 2016-02-25
AU2012213056A1 (en) 2013-07-25
MX2013008225A (es) 2013-08-12
AU2017204639A1 (en) 2017-07-27
CA2824835A1 (en) 2012-08-09
JP2014504630A (ja) 2014-02-24
SG191872A1 (en) 2013-08-30
KR20130124551A (ko) 2013-11-14
RU2013136350A (ru) 2015-03-27
KR20160031038A (ko) 2016-03-21
JP2018109059A (ja) 2018-07-12
EP2670400A1 (en) 2013-12-11
IL227770A0 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
CN103415285A (zh) 包含阿片样激动剂和被隔离的拮抗剂的药物组合物
JP5566102B2 (ja) 医薬組成物
CA2665726C (en) Pharmaceutical compositions
EP2197427A2 (en) A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
WO2013092589A1 (en) Multiple unit pellet tablet formulation comprising an opioid
HK1191570A (en) Pharmaceutical composition comprising opioid agonist and sequestered antagonist
AU2014250614B2 (en) A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
AU2017239533A1 (en) Pharmaceutical compositions
AU2013211445A1 (en) Pharmaceutical Compositions
HK1176867A (en) Pharmaceutical composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1191570

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20131127

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1191570

Country of ref document: HK